IL154378A0 - Compounds for the treatment of addictive disorders - Google Patents

Compounds for the treatment of addictive disorders

Info

Publication number
IL154378A0
IL154378A0 IL15437801A IL15437801A IL154378A0 IL 154378 A0 IL154378 A0 IL 154378A0 IL 15437801 A IL15437801 A IL 15437801A IL 15437801 A IL15437801 A IL 15437801A IL 154378 A0 IL154378 A0 IL 154378A0
Authority
IL
Israel
Prior art keywords
compounds
treatment
addictive disorders
addictive
disorders
Prior art date
Application number
IL15437801A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL154378A0 publication Critical patent/IL154378A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
IL15437801A 2000-08-16 2001-08-13 Compounds for the treatment of addictive disorders IL154378A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22571400P 2000-08-16 2000-08-16
US26361001P 2001-01-23 2001-01-23
PCT/US2001/025603 WO2002013807A2 (en) 2000-08-16 2001-08-13 Compounds for the treatment of addictive disorders

Publications (1)

Publication Number Publication Date
IL154378A0 true IL154378A0 (en) 2003-09-17

Family

ID=26919847

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15437801A IL154378A0 (en) 2000-08-16 2001-08-13 Compounds for the treatment of addictive disorders

Country Status (17)

Country Link
US (2) US6841557B2 (xx)
EP (1) EP1363634A2 (xx)
JP (1) JP2004506621A (xx)
KR (1) KR20030024877A (xx)
AR (1) AR030364A1 (xx)
AU (2) AU2001283393B2 (xx)
BR (1) BR0112939A (xx)
CA (1) CA2413762A1 (xx)
CZ (1) CZ200380A3 (xx)
EA (1) EA200300271A1 (xx)
IL (1) IL154378A0 (xx)
MX (1) MXPA03001472A (xx)
NO (1) NO20030717D0 (xx)
NZ (1) NZ524741A (xx)
PE (1) PE20020288A1 (xx)
PL (1) PL363365A1 (xx)
WO (1) WO2002013807A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
MXPA05003513A (es) * 2002-10-04 2005-06-03 Pharmacia Corp Composiciones farmaceuticas para tratamiento de enfermedad de parkinson.
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
DK2618826T3 (en) * 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) * 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
WO1992000282A1 (en) * 1990-06-29 1992-01-09 The Upjohn Company Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
JP3176063B2 (ja) 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
TW252979B (xx) * 1992-12-24 1995-08-01 Erba Carlo Spa
CN1046723C (zh) * 1993-04-06 1999-11-24 艾博特公司 四环化合物、含有它们的药物组合物及其用途
ATE182590T1 (de) 1993-12-28 1999-08-15 Upjohn Co Heterozyklische verbindungen für die behandlung von kardiovaskular- und zentralnervensystem störungen
GB9407637D0 (en) * 1994-04-18 1994-06-08 Erba Carlo Spa Serotoninergic abeo-ergoline derivatives
US5874477A (en) * 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9603226D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Heterocyclyl-ergoline derivatives
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US20020010197A1 (en) * 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
CA2405565A1 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome

Also Published As

Publication number Publication date
PL363365A1 (en) 2004-11-15
JP2004506621A (ja) 2004-03-04
EP1363634A2 (en) 2003-11-26
NZ524741A (en) 2005-01-28
KR20030024877A (ko) 2003-03-26
WO2002013807A2 (en) 2002-02-21
AU2001283393B2 (en) 2005-09-22
NO20030717L (no) 2003-02-14
BR0112939A (pt) 2005-11-01
US20020049206A1 (en) 2002-04-25
EA200300271A1 (ru) 2004-02-26
AR030364A1 (es) 2003-08-20
MXPA03001472A (es) 2003-06-06
CA2413762A1 (en) 2002-02-21
PE20020288A1 (es) 2002-03-31
US20030078273A1 (en) 2003-04-24
WO2002013807A3 (en) 2003-09-25
AU8339301A (en) 2002-02-25
NO20030717D0 (no) 2003-02-14
US6841557B2 (en) 2005-01-11
CZ200380A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
ZA200401004B (en) Combination for the treatment of inflammatory disorders
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
AU8339301A (en) Compounds for the treatment of addictive disorders
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
EP1278538A4 (en) ANTIBODIES BINDING TO CD18 AND INHIBITING STENOSE-RELATED DISORDERS
GB0013105D0 (en) Therapeutic compounds
GB9918058D0 (en) Compound for treatment of gi disorders
SI1200447T1 (en) Oxazinocarbazoles for the treatment of cns diseases
AUPQ696900A0 (en) Novel therapy for hyperlipidaemia-associated disorders
AUPR085100A0 (en) Novel therapy for hyperlipidaemia-associated disorders
GB0004998D0 (en) The treatment of functional gastrointestinal disorders